Want to see UG full AI Analyst Report?
UG Stock Chart & Stats
$7.62
$0.63(8.27%)
At close: 4:00 PM EDT
$7.62
$0.63(8.27%)
Day’s Range― - ―
52-Week Range$5.58 - $8.78
Previous CloseN/A
Volume18.43K
Average Volume (3M)6.29K
Market Cap
$32.85M
Enterprise Value$23.21
Total Cash (Recent Filing)$8.93M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)13.2
Beta0.25
Next Earnings
Nov 11, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield4.2%
Share Statistics
EPS (TTM)0.54
Shares Outstanding4,594,319
10 Day Avg. Volume6,994
30 Day Avg. Volume6,291
Financial Highlights & Ratios
PEG Ratio-0.38
Price to Book (P/B)2.52
Price to Sales (P/S)2.68
P/FCF Ratio14.83
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Debt-Free Balance SheetZero leverage materially limits financial risk, interest burden, and refinancing exposure. This gives United-Guardian flexibility to fund operations, withstand industry fluctuations, and preserve capital for product development or shareholder returns.
High-Quality Cash GenerationCash conversion closely tracks reported earnings, supporting the reliability of profits. Strong TTM free cash flow growth and operating cash coverage provide internal funding capacity for investment, dividends, and resilience through weaker demand.
Established Shareholder ReturnsA three-decade dividend record and recent increase indicate a durable capital-return policy supported by board confidence in financial performance and growth initiatives. This can reinforce investor support while reflecting disciplined cash allocation.
Bears Say
Modest Revenue GrowthLow-single-digit growth indicates limited current expansion in the company’s specialty ingredients markets. Without stronger volume, pricing, or new-product contribution, revenue growth may constrain operating leverage and the pace of earnings improvement.
Uneven Operating PerformanceThe multi-year pattern shows that profitability is not consistently maintained across market conditions. Margin and revenue volatility can make earnings less predictable and may limit confidence in sustainable returns despite healthy current margins.
End-Market And Customer DependenceUnited-Guardian’s sales depend on customers qualifying and producing finished products, exposing volumes to formulation cycles and end-market conditions. This can create longer adoption timelines and uneven demand across its specialized applications.
United-Guardian News
UG FAQ
What was United-Guardian’s price range in the past 12 months?
United-Guardian lowest stock price was $5.58 and its highest was $8.78 in the past 12 months.
What is United-Guardian’s market cap?
United-Guardian’s market cap is $32.85M.
When is United-Guardian’s upcoming earnings report date?
United-Guardian’s upcoming earnings report date is Nov 11, 2026 which is in 78 days.
How were United-Guardian’s earnings last quarter?
United-Guardian released its earnings results on Aug 07, 2026. The company reported $0.159 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is United-Guardian overvalued?
According to Wall Street analysts United-Guardian’s price is currently Overvalued.
Does United-Guardian pay dividends?
United-Guardian pays a Semiannually dividend of $0.3 which represents an annual dividend yield of 4.2%. See more information on United-Guardian dividends here
What is United-Guardian’s EPS estimate?
United-Guardian’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does United-Guardian have?
United-Guardian has 4,594,319 shares outstanding.
What happened to United-Guardian’s price movement after its last earnings report?
United-Guardian reported an EPS of $0.159 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 0.76%.
Which hedge fund is a major shareholder of United-Guardian?
Currently, no hedge funds are holding shares in UG
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
United-Guardian Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-43.84%
12-Months-Change
Fundamentals
Return on Equity
4.20%
Trailing 12-Months
Asset Growth
1.48%
Trailing 12-Months
Company Description
United-Guardian
United-Guardian, Inc., operating both domestically and globally, specializes in the development, production, and distribution of a diverse range of cosmetic raw materials, pharmaceutical solutions, medical-grade lubricants, and proprietary industrial chemicals. Its extensive cosmetic ingredients catalog includes the LUBRAJEL line of water-based moisturizing and lubricating gel formulations, featuring variants such as LUBRAJEL NATURAL (derived from natural sources), LUBRAJEL MARINE, and LUBRASIL II SB (a silicone-infused LUBRAJEL formulation). Other key offerings in this category are LUBRAJEL II XD; B-122, a powdered lubricant suitable for pressed powders, eyeliners, blushes, and industrial uses; KLENSOFT, a surfactant for shampoos, shower gels, and makeup removers; and ORCHID COMPLEX, an oil-soluble base for skin creams, lotions, and cleansers. For medical applications, United-Guardian provides lubricants like LUBRAJEL RR and RC, which are water-based gels specifically designed for urinary catheters. LUBRAJEL MG serves to lubricate urinary catheters, pre-lubricated enema tips, and other medical devices. The company also offers LUBRAJEL LC and LUBRAJEL FA, specialized LUBRAJEL formulations tailored for oral care, alongside LUBRAJEL FLUID for lubricating various water-soluble products. The pharmaceutical portfolio features RENACIDIN, a prescription medication for preventing and dissolving calcifications in urethral catheters and the urinary bladder. Also included is CLORPACTIN WCS-90, an antimicrobial agent effective against infections in the urinary bladder, localized peritoneal infections, and infections affecting the eyes, ears, nose, throat, and sinuses. Industrial products comprise DESELEX, a sequestering and chelating agent vital for detergent manufacturing, and THOROCLENS, a powerful chlorine-based industrial cleaning solution. The firm also dedicates resources to research and development, primarily focusing on advancing cosmetic ingredients. Products are brought to market through a robust network of marketing partners, distributors, and wholesalers. Established in 1942, United-Guardian maintains its headquarters in Hauppauge, New York.
Technical Analysis
Church & Dwight
―
Clorox
―
Colgate-Palmolive
―
Honest Company
―
Grove Collaborative Holdings
―
Ownership Overview
22.45% Insiders
6.86% Mutual Funds
8.54% Other Institutional Investors
58.00% Public Companies and
Individual Investors